Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy

Completed

• Conditions: Central Nervous System Lymphoma; AIDS Related Lymphoma
• Interventions: Other: Retrospective survival analysis

• Registration Number: NCT03690895
• Lead Sponsor: Fondation Ophtalmologique Adolphe de Rothschild

Brief Summary

This study aims at describing survival rates over time (Kaplan-Meier estimator) in patients suffering from AIDS-related primary central nervous system lymphoma who were diagnosed from 1996 to 2014 and treated with infusions of high-dose methotrexate and combined antiretroviral therapy.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-03-15
• Primary Completion: 2016-10-01
• Study Completion: 2016-10-01
• Status Verified: 2018-09
• Study First Submitted: 2018-09-26
• Study First Submitted QC: 2018-09-28
• Last Update Submitted: 2018-09-28
• Study First Posted: 2018-10-01
• Last Update Posted: 2018-10-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 51

Inclusion Criteria

• HIV infection
• AIDS-related primary central nervous system lymphoma
• treated with at least one infusion of methotrexate and combine antiretroviral therapy

Exclusion Criteria

• prior non-Hodgkin lymphoma

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Cases	Retrospective survival analysis	-

Primary Outcome Measures

Name	Time	Method
Median duration of survival after diagnosis of lymphoma (years)	At the time of systematic files review (jan 2014) - average follow-up 7 years

Trial Locations

Locations (1)

Fondation Ophtalmologique A. de Rotchschild; 🇫🇷 Paris, France